Attomol

Lipsia, Germany· Est. 2005

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Attomol is a privately held, revenue-generating diagnostics company with over 30 employees, producing CE-marked in-vitro diagnostic (IVD) tests. Its core technology platform leverages allele-specific PCR, real-time PCR, strip tests, and multiplex bead assays for applications in autoimmune diseases and infectious disease research. The company has established key academic and network partnerships in Germany to drive R&D and is positioned in the growing molecular diagnostics market, though it faces competition from larger players and depends on continuous innovation.

Autoimmune DiseasesInfectious Diseases

Technology Platform

Platform utilizing allele-specific PCR, real-time PCR, strip tests (lateral flow), and multiplex bead assays for the detection of genetic mutations, autoantibodies, and pathogen-specific antibodies. Also offers automated DNA purification systems.

Opportunities

Growth in the autoimmune diagnostics market and the potential to convert research-use-only bead assays into certified IVD tests present significant opportunities.

Strategic academic partnerships provide a low-cost R&D engine for expanding the product portfolio.

Risk Factors

Faces intense competition from large diagnostics corporations and must manage the costly regulatory transition to the EU's new IVDR.

Technological disruption in core areas like mutation detection could threaten existing product lines.

Competitive Landscape

Operates in a crowded niche competing against large IVD multinationals (e.g., Roche, Abbott) and many small-to-mid-sized specialty diagnostics firms. Differentiation is achieved through patented products, direct customer support, and flexibility in providing tailored solutions.